Piromidic acid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Piromidic acid
Accession Number
DB13744
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
3I12WH4EWF
CAS number
19562-30-2
Weight
Average: 288.307
Monoisotopic: 288.122240391
Chemical Formula
C14H16N4O3
InChI Key
RCIMBBZXSXFZBV-UHFFFAOYSA-N
InChI
InChI=1S/C14H16N4O3/c1-2-17-8-10(13(20)21)11(19)9-7-15-14(16-12(9)17)18-5-3-4-6-18/h7-8H,2-6H2,1H3,(H,20,21)
IUPAC Name
8-ethyl-5-oxo-2-(pyrrolidin-1-yl)-5H,8H-pyrido[2,3-d]pyrimidine-6-carboxylic acid
SMILES
CCN1C=C(C(O)=O)C(=O)C2=CN=C(N=C12)N1CCCC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Piromidic acid is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Piromidic acid is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Piromidic acid is combined with 4-hydroxycoumarin.
AbexinostatThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Acebutolol.
AcenocoumarolThe risk or severity of bleeding can be increased when Piromidic acid is combined with Acenocoumarol.
AceprometazineThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Aceprometazine.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Piromidic acid.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Piromidic acid.
AdenosineThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Adenosine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
4689
ChEBI
32019
ChEMBL
CHEMBL311350
Wikipedia
Piromidic_acid
ATC Codes
J01MB03 — Piromidic acid

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.21 mg/mLALOGPS
logP0.42ALOGPS
logP1.59ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)5.61ChemAxon
pKa (Strongest Basic)3.03ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.63 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity78.97 m3·mol-1ChemAxon
Polarizability29.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrido[2,3-d]pyrimidines. These are compounds containing the pyrido[2,3-d]pyrimidine ring system, which is a pyridopyrimidine isomer with three ring nitrogen atoms at the 1-, 3-, and 8- position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridopyrimidines
Sub Class
Pyrido[2,3-d]pyrimidines
Direct Parent
Pyrido[2,3-d]pyrimidines
Alternative Parents
Pyridinecarboxylic acids / Dialkylarylamines / Aminopyrimidines and derivatives / Vinylogous amides / Pyrrolidines / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Pyrido[2,3-d]pyrimidine / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Dialkylarylamine / Aminopyrimidine / Pyrimidine / Pyridine / Heteroaromatic compound / Vinylogous amide / Pyrrolidine
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:47 / Updated on July 24, 2019 06:00